Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Eidos Therapeutics, Inc is a biotechnology business based in the US. Eidos Therapeutics shares (EIDX) are listed on the NASDAQ and all prices are listed in US Dollars. Eidos Therapeutics employs 64 staff and has a trailing 12-month revenue of around USD$26.7 million.
|Latest market close||USD$81.21|
|52-week range||USD$37 - USD$76.94|
|50-day moving average||USD$54.7676|
|200-day moving average||USD$47.8488|
|Wall St. target price||USD$62.81|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.273|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||-8.45%|
|1 month (2020-11-06)||11.69%|
|3 months (2020-09-04)||98.12%|
|6 months (2020-06-04)||65.53%|
|1 year (2019-12-04)||37.99%|
|2 years (2018-12-04)||494.07%|
|3 years (2017-12-02)||N/A|
|5 years (2015-12-02)||N/A|
|Revenue TTM||USD$26.7 million|
|Gross profit TTM||USD$24.2 million|
|Return on assets TTM||-23.85%|
|Return on equity TTM||-45.33%|
|Market capitalisation||USD$2.9 billion|
TTM: trailing 12 months
There are currently 1.9 million Eidos Therapeutics shares held short by investors – that's known as Eidos Therapeutics's "short interest". This figure is 3.4% up from 1.9 million last month.
There are a few different ways that this level of interest in shorting Eidos Therapeutics shares can be evaluated.
Eidos Therapeutics's "short interest ratio" (SIR) is the quantity of Eidos Therapeutics shares currently shorted divided by the average quantity of Eidos Therapeutics shares traded daily (recently around 84120.328010358). Eidos Therapeutics's SIR currently stands at 23.17. In other words for every 100,000 Eidos Therapeutics shares traded daily on the market, roughly 23170 shares are currently held short.
However Eidos Therapeutics's short interest can also be evaluated against the total number of Eidos Therapeutics shares, or, against the total number of tradable Eidos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Eidos Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Eidos Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.177% of the tradable shares (for every 100,000 tradable Eidos Therapeutics shares, roughly 177 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Eidos Therapeutics.
Find out more about how you can short Eidos Therapeutics stock.
We're not expecting Eidos Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Eidos Therapeutics's shares have ranged in value from as little as $37 up to $76.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eidos Therapeutics's is -0.411. This would suggest that Eidos Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Eidos Therapeutics has bucked the trend.
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.